Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapies designed to silence disease-causing genes. Its pipeline targets conditions such as liver and cardiometabolic disorders, using proprietary delivery technology to get siRNA into specific tissues. The company partners with larger drug makers while advancing its own clinical candidates.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 27.8 | — | -175.2 | — |
| Q3 2025 | 256.5 | — | -23.8 | — |
| Q4 2025 | 264 | — | 30.8 | — |
| Q1 2026 | 73.7 | — | -132.7 | — |
| Q2 2026 | 75.3 | 171% | -194.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: American Airlines Group Inc. (AAL), Wynn Resorts, Limited (WYNN), Morningstar, Inc. (MORN), CAE Inc. (CAE), Netskope, Inc. (NTSK), Dropbox, Inc. (DBX)